Free Trial
NASDAQ:IART

Integra LifeSciences (IART) Stock Price, News & Analysis

Integra LifeSciences logo
$15.61 -0.27 (-1.70%)
As of 02:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Integra LifeSciences Stock (NASDAQ:IART)

Advanced

Key Stats

Today's Range
$15.49
$16.35
50-Day Range
$13.18
$15.99
52-Week Range
$11.06
$27.13
Volume
510,371 shs
Average Volume
1.05 million shs
Market Capitalization
$1.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.17
Consensus Rating
Reduce

Company Overview

Integra LifeSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

IART MarketRank™: 

Integra LifeSciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 506th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Integra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on 2 buy ratings, 2 hold ratings, and 4 sell ratings.

  • Upside/Downside

    The consensus price target for Integra LifeSciences is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Integra LifeSciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Integra LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Integra LifeSciences are expected to grow by 2.04% in the coming year, from $2.45 to $2.50 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Integra LifeSciences is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Integra LifeSciences is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Integra LifeSciences has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Integra LifeSciences' valuation and earnings.
  • Percentage of Shares Shorted

    9.48% of the float of Integra LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Integra LifeSciences has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Integra LifeSciences has recently decreased by 2.80%, indicating that investor sentiment is improving.
  • Dividend Yield

    Integra LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Integra LifeSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.48% of the float of Integra LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Integra LifeSciences has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Integra LifeSciences has recently decreased by 2.80%, indicating that investor sentiment is improving.
  • News Sentiment

    Integra LifeSciences has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Integra LifeSciences this week, compared to 6 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Integra LifeSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.54% of the stock of Integra LifeSciences is held by insiders.

  • Percentage Held by Institutions

    84.78% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Integra LifeSciences' insider trading history.
Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IART Stock News Headlines

7 market signals flashing red right now
Right now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all flashing red at the same time.tc pixel
Citi Reaffirms Their Sell Rating on Integra Lifesciences (IART)
See More Headlines

IART Stock Analysis - Frequently Asked Questions

Integra LifeSciences' stock was trading at $22.68 at the beginning of 2025. Since then, IART stock has decreased by 29.7% and is now trading at $15.9340.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) issued its earnings results on Thursday, July, 31st. The life sciences company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. The company's revenue was down .6% compared to the same quarter last year.
Read the conference call transcript
.

Integra LifeSciences shares split on Tuesday, January 3rd 2017.The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

The following companies are subsidiaries of Integra LifeSciences: ACell Inc, Rebound Therapeutics, Arkis BioSciences, Codman Neuro, TGX Medical Systems, Derma Sciences, Tekmed Instruments S.p.A, and more.

Top institutional shareholders of Integra LifeSciences include Assenagon Asset Management S.A. (0.58%), Olstein Capital Management L.P. (0.18%), Wedge Capital Management L L P NC (0.08%) and Exchange Traded Concepts LLC (0.05%). Insiders that own company stock include Stuart Essig, Michael J Mcbreen, Lisa Evoli, Witte Jan De and Jeffrey Mosebrook.
View institutional ownership trends
.

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Integra LifeSciences investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Tesla (TSLA) and Home Depot (HD).

Company Calendar

Last Earnings
7/31/2025
Today
10/22/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IART
CIK
917520
Employees
4,396
Year Founded
1989

Price Target and Rating

High Price Target
$25.00
Low Price Target
$12.00
Potential Upside/Downside
+1.8%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
6.48
P/E Growth
N/A
Net Income
-$6.94 million
Net Margins
-30.87%
Pretax Margin
-34.46%
Return on Equity
12.15%
Return on Assets
4.32%

Debt

Debt-to-Equity Ratio
1.18
Current Ratio
1.23
Quick Ratio
0.73

Sales & Book Value

Annual Sales
$1.61 billion
Price / Sales
0.77
Cash Flow
$4.50 per share
Price / Cash Flow
3.53
Book Value
$20.03 per share
Price / Book
0.79

Miscellaneous

Outstanding Shares
77,910,000
Free Float
75,153,000
Market Cap
$1.24 billion
Optionable
Optionable
Beta
1.21

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:IART) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners